What Doses Appeared in the Published BPC-157 Studies

Research doses, in plain terms

The doses used in BPC-157 animal studies range across twelve orders of magnitude — from picogram to microgram per kilogram of body weight per day — and positive outcomes are reported across the entire span. That breadth is unusual for any bioactive compound and is noted in independent reviews as a point of interest, and for some researchers, of skepticism. The most common rat dose is 10 micrograms per kilogram per day given intraperitoneally (directly into the abdominal cavity) — a route not used in human clinical practice. The only human pharmacokinetic data come from a two-person intravenous safety pilot: plasma levels returned to baseline within 24 hours, consistent with a half-life under 30 minutes. All dose information on this page records what appeared in published studies. None of it constitutes a recommendation for human use. BPC-157 is not approved for any human indication.

Animal study doses: the published range

The BPC-157 rodent literature covers an extraordinarily wide dose range — twelve orders of magnitude, from picogram to microgram per kilogram of body weight — and reports positive outcomes across the entire span. This is an unusual feature of the literature that independent reviewers have noted as a point of interest and, for some, of skepticism.

The most commonly used systemic dose in rat studies is 10 μg/kg/day administered intraperitoneally, which appears in a large proportion of the Sikiric group's studies including the 2006 Achilles tendon work ^[1], the 2011 NSAID toxicity study ^[7], and multiple gastrointestinal healing papers. This is also the dose used in the 2022 cardioprotection study ^[12] and represents the primary reference point when research summaries discuss the compound's animal pharmacology.

Studies have also used 10 ng/kg/day (one-thousandth of the standard dose) and 10 pg/kg/day (one-millionth) intraperitoneally, with outcomes described as comparable. The 2019 spinal cord injury study ^[10] additionally used 200 μg/kg (a substantially higher single dose) in the acute post-injury administration arm.

Oral administration in drinking water has been studied at concentrations of 0.16 μg/mL or 0.16 ng/mL — corresponding to approximately 2 μg/kg/day or 2 ng/kg/day in a rat consuming roughly 12 mL of water daily. Oral dosing has been used in the anastomosis healing research ^[8] and the 2025 quadriceps detachment study ^[11], where the drinking water route was compared against intraperitoneal delivery and found to produce equivalent outcomes.

Topical application doses in wound and burn models ranged from 200 to 800 ng/mL in the 2015 alkali burn study ^[5]. In vitro concentrations of 0.1–0.5 μg/mL were used in the tendon fibroblast cell culture work examining growth hormone receptor upregulation ^[2]. Ophthalmic application was studied at 2 pg/mL to 2 μg/mL in the corneal model ^[17].

The rabbit bone defect study used 10 μg/kg administered by local injection into the defect and intermittent intramuscular injection on days 7, 9, 14, and 16 ^[4]. The ischemia-reperfusion distant organ study used a single 20 μg/kg intraperitoneal dose at the start of the procedure ^[13].

Routes of administration studied

The published literature has examined BPC-157 across nine distinct routes of administration, a breadth that reflects both its stability across physiological environments and the research group's interest in establishing route-agnostic efficacy.

Intraperitoneal (i.p.) injection is the most common route in rat studies — it is also the least clinically analogous, as it delivers compound directly into the peritoneal cavity, an administration mode not used in human clinical practice. Subcutaneous injection has been used in some protocols. Intragastric gavage (direct delivery into the stomach via a tube) has been used for oral-route verification. Oral administration via drinking water represents a more physiologically relevant oral route and has been used in the anastomosis ^[8] and quadriceps ^[11] studies.

Topical application via bath (immersion of the wound area in BPC-157 solution) has been used in some wound healing protocols. Local injection directly into the site of injury — the tendon-bone interface, the bone defect — has been used for musculoskeletal studies ^[4]. Ophthalmic drops were the route for the corneal alkali burn model ^[17]. Intravesicular (bladder instillation) was the route in the interstitial cystitis human pilot ^[15]. Intravenous infusion was used in the 2025 human safety pilot ^[16].

Across all routes, the published studies report positive outcomes — including oral administration, which is mechanistically difficult to explain for a peptide that might be expected to undergo gastric and intestinal proteolysis. The stability data offer a partial explanation: BPC-157 retains structural integrity in gastric acid for more than 24 hours, a property that may allow some fraction to reach the small intestine intact for absorption. However, the oral pharmacokinetics of BPC-157 have not been formally characterized in the published literature.

Stability and formulation context

BPC-157 is stable in gastric acid for more than 24 hours — a notable property that distinguishes it from most gastrointestinal peptide fragments such as EGF and TGF-alpha, which survive only minutes in that environment ^[6]. This stability in an acidic environment at physiological temperature was a defining characteristic of the original BPC research program and is one of the features that made oral administration studies plausible.

In saline at physiological pH, the peptide is also stable and requires no carrier protein or excipient for administration — the published studies use aqueous saline solutions for both intraperitoneal and drinking water preparations. Research-grade BPC-157 preparations in the literature are typically specified at HPLC purity greater than 95%.

No standardized manufacturing specifications, purity requirements, or dosage forms for research-grade BPC-157 have been established by any regulatory body. The absence of such standards is among the concerns cited in the FDA's Category 2 designation — manufacturing impurity concerns were listed alongside safety risk concerns and insufficient clinical data as the basis for the 2023 classification ^[14].

Human pharmacokinetic data: what little exists

The 2025 intravenous safety pilot in two healthy adults provides the only formal pharmacokinetic data for BPC-157 in humans. At doses up to 20 mg administered by IV infusion, plasma levels returned to baseline within 24 hours, consistent with a plasma half-life under 30 minutes ^[16]. This is a short half-life for a compound often discussed in multi-injection daily dosing contexts, and the implication for oral bioavailability — where first-pass metabolism would presumably affect plasma levels — has not been characterized.

Rat pharmacokinetic data are sparse in the published literature. The preponderance of the evidence describes pharmacodynamic outcomes (healing, recovery, organ protection) without accompanying toxicokinetic or pharmacokinetic profiles. The absence of formal PK data for most study designs is a limitation acknowledged by the 2025 McGuire et al. review ^[15].

The ulcerative colitis Phase 2 trial (PL 14736, Pliva) did not publish the full clinical dataset including pharmacokinetics in a peer-reviewed form accessible in the literature reviewed here ^[14]. The interstitial cystitis pilot similarly did not report plasma concentration data for the intravesicular route ^[15].

All dosage information on this page is drawn from published preclinical research and the limited human pilot data described above. It is presented as a record of what was studied, not as a basis for human administration decisions. BPC-157 is not approved for any human indication and is not available through the US compounding pharmacy system following the September 29, 2023 FDA 503A Category 2 classification.